<?xml version="1.0" encoding="UTF-8"?>
<ref id="B149-jcm-09-02084">
 <label>149.</label>
 <element-citation publication-type="gov">
  <person-group person-group-type="author">
   <collab>U.S. Food and Drug Administration</collab>
  </person-group>
  <article-title>Recommendations for Investigational COVID-19 Convalescent Plasma | FDA</article-title>
  <comment>Available online: 
   <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma</ext-link>
  </comment>
  <date-in-citation content-type="access-date" iso-8601-date="2020-05-04">(accessed on 4 May 2020)</date-in-citation>
 </element-citation>
</ref>
